Atlas Trials

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

Clinical trial NCT06573151 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06573151
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2024-09-01
Primary completion
2027-07-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.